Infinity Pharmaceuticals Inc. Reports Updated Phase 1 Data Of IPI-145 In Indolent Non-Hodgkin Lymphoma At American Society of Hematology Annual Meeting
Published: Dec 09, 2013
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced updated Phase 1 data from an ongoing study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), a potentially fatal hematologic malignancy (blood cancer). Data from the study showed that IPI-145 was clinically active, with an overall response rate of 73 percent, including three complete responses, among patients receiving IPI-145 dosed at = 25 mg twice daily (BID).
Help employers find you! Check out all the jobs and post your resume.